Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction

Clinical and Translational Science

Volumn 2, Issue 2, 2009, Pages 134-142

  Kanashiro Takeuchi, Rosemeire M ^a   Heidecker, Bettina ^a   Lamirault, Guillaume ^a   Dharamsi, Jennifer W ^b   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aldosterone antagonism; Feart failure; Gene expression; Myocardial infarction; Sex

Indexed keywords

ALDOSTERONE RECEPTOR; EPLERENONE; PLACEBO; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; MALE; MICROARRAY ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SEX DIFFERENCE; TRANSCRIPTOMICS; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CLUSTER ANALYSIS; COMPLICATION; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; WISTAR RAT;

ANIMALIA; RATTUS;

ANIMALS; CLUSTER ANALYSIS; FEMALE; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; PLACEBOS; RATS; RATS, WISTAR; SEX CHARACTERISTICS; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 77952417047     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00094.x     Document Type: Article

References (48)

1. Duprez DA. Is the female heart more sensitive to aldosterone for early remodeling? Hypertension. 2004; 43(5): 936-937.
2. Wu JC, Nasseri BA, Bloch KD, Picard MH, Scherrer-Crosbie M. Influence of sex on ventricular remodeling after myocardial infarction in mice. J Am Soc Echocardiogr. 2003; 16(11) 1158-1162.
3. Cohn JN. Hormones, drugs, remodeling and outcome in heart failure and after myocardia infarction. Cordiovosc Drugs Ther. 2001; 15(1): 9-10.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709-717.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309-1321.
6. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW. Relations of serum aldosterone to cardiac structure: Gender-related differences in the Framingham Heart Study. Hypertension. 2004; 43 (5): 957-962.
7. Arias-Loza PA, Hu K, Dienesch C, Mehfich AM, Konig S, Jazbutyte V, Neyses L, Hegele-Hartung C, Heinrich Fritzemeier K, Pelzer T. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension. 2007; 50(2) 432-438.
8. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995; 92(2): 175-182.
9. Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997; 416(1): 107-112.
10. Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J Cardiovasc Pharmacol. 1999; 33(3): 451-460.
11. Radin MJ, Chu YY, Hoepf TM, McCune SA. Treatment of obese female and male SHHF; Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: Effects on body weight, fat distribution, insulin resistance and systolic pressure. Obes Res. 1993; 1(6) 433-442.
12. Radin MJ, Jenkins JE, McCune SA, Jurin RR, Hamlin RL. Effects of enalapril and clonidine on glomerular structure, function, and atria I natriuretic peptide receptors in SHHF/Mcc-cp rats. J Cardiovasc Pharmacol. 1992; 19(3): 464-472.
13. Sharkey LC, Holycross BJ, McCune SA, Radin MJ. Obese female SHHF/ Mcc-fa(cp) rats resist antihypertensive effects of renin-angiotensin system inhibition. Clin Exp Hypertens. 2001; 23(3) 227-239.
14. Adams KF, Jr, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, Jensen LR, Tomasko L, Koch G. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996; 28(7): 1781-1788.
15. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res. 1979; 44(4): 503-512.
16. Gaspard GJ, Pasumarthi KB. Quantification of cardiac fibrosis by colour-subtractive computer-assisted image analysis. Clin Exp Pharmacol Physiol. 2008; 35 (5-6): 679-686.
17. Zeeberg BR, Qin H, Narasimhan S, Sunshine M, Cao H, Kane DW, Reimers M, Stephens RM, Bryant D, Burt SK, Elnekave E, Hari DM, Wynn TA, Cunningham-Rundles C, Stewart DM, Nelson D, Weinstein JN. High-Throughput GoMiner, an 'industrial-strength'integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics. 2005; 6: 168.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998; 95 (25): 14863-14868.
19. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen C, Hunkapiller K, Jensen RV, Knight CR, Lee KY, Ma Y, Maqsodi B, Papallo A, Peters EH, Poulter K, Ruppel PL, Samaha RR, Shi L, Yang W, Zhang L, Goodsaid FM. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006; 24(9): 1115-1122.
20. Schunkert H, Hense HW, Muscholl M, Luchner A, Kurzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997; 77(1): 24-31.
21. Harvey BJ, Condliffe S, Doolan CM. Sex and salt hormones: Rapid effects in epithelia. News Physiol Sci. 2001; 16: 174-177.
22. Hoshi-Fukushima R, Nakamoto H, Imai H, Kanno Y, Ishida Y, Yamanouchi Y, Suzuki H. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am J Nephrol. 2008; 28(3): 413-423.
23. Cavasin MA, Tao Z, Menon S, Yang XP. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci. 2004; 75(18): 2181-2192.
24. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 2001; 281(2): H647-H654.
25. Enomoto S, Yoshiyama M, Omura T, Matsumoto R, Kusuyama T, Kim S, Izumi Y, Akioka K, Iwao H, Takeuchi K, Yoshikawa J. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart. 2005; 91(12) 1595-1600.
26. Jin H, Yang R, Awad TA, Wang F, Li W, Williams SP, Ogasawara A, Shimada B, Williams PM, de Feo G, Paoni NF Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation. 2001; 103(5): 736-742.
27. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res. 1998; 83(8) 860-869.
28. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, Terrand J, Lerch R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc Res. 2001; 52(3): 407-416.
29. Silvestre JS, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999; 99(20) 2694-2701.
30. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999; 99(23) 3063-3070.
31. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angioge-nesis and causes cardiac failure. Nat Med. 1999; 5(10): 1135-1142.
32. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106(1): 55-62.
33. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, Swynghedauw B, Delcayre C Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 1997; 76(5): 729-738.
34. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology. 2004; 145(7): 3153-3157.
35. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Mozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107(20): 2559-2565.
36. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol. 2002; 161(5): 1773-1781.
37. Kressler D, Schreiber SN, Knutti D, Kralli A. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem. 2002; 277(16): 13918-13925.
38. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 2006; 116(3): 598-606.
39. Lygate CA, Hubert K, Monfared M, Cole MA, Clarke K, Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res. 2003; 58(3): 632-637.
40. Thiemermann C Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure. Br J Pharmacol. 2004; 142(6): 1049-1051.
41. Reiss K, Meggs LG, Li P, Olivetti G, Capasso JM, Anversa P. Upregulation of IGF1, IGF1-receptor, and late growth related genes in ventricular myocytes acutely after infarction in rats. J Cell Physiol 1994; 158(1): 160-168.
42. Kluge A, Zimmermann R, Munkel B, Mohri M, Sacks, Schaper J, Schaper W. Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res 1995; 29(3): 407-415.
43. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure J Clin Invest. 1995; 95(2): 619-627.
44. Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, Kawauchi J, Sunamori M, Marumo F, Kitajima S, Ikeda MA. Critical role of cyclin Dl nuclear import in cardio-myocyte proliferation. Circ Res. 2003; 92(1): El2-el9.
45. Reiss K, Cheng W, Pierzchalski P, Kodali S, Li B, Wang S, Liu Y, Anversa P. Insulin-like growth factor-1 receptor and its ligand regulate the reentry of adult ventricular myocytes into the cell cycle. Exp Cell Res. 1997; 235(1): 198-209.
46. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002; 172(3): 423-440.
47. Kluge A, Zimmermann R, Weihrauch D, Mohri M, Sack S, Schaper J, Schaper W. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res. 1997; 33(2): 324-331.
48. Cook CS, Zhang L, Ames GB, Fischer J, Zhang J, Levin S. Single- and repeated-dose pharma-cokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. Xenobiotica. 2003; 33(3): 305-321.